RETA vs. CYTK, ISEE, ZLAB, FOLD, MRVI, ACAD, PTCT, BHC, RARE, and CERE
Should you be buying Reata Pharmaceuticals stock or one of its competitors? The main competitors of Reata Pharmaceuticals include Cytokinetics (CYTK), IVERIC bio (ISEE), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), Bausch Health Companies (BHC), Ultragenyx Pharmaceutical (RARE), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Reata Pharmaceuticals vs.
Reata Pharmaceuticals (NASDAQ:RETA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
Reata Pharmaceuticals has higher earnings, but lower revenue than Cytokinetics. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Reata Pharmaceuticals had 3 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Reata Pharmaceuticals and 9 mentions for Cytokinetics. Reata Pharmaceuticals' average media sentiment score of 0.46 beat Cytokinetics' score of -0.17 indicating that Reata Pharmaceuticals is being referred to more favorably in the media.
Reata Pharmaceuticals presently has a consensus target price of $96.89, suggesting a potential upside of 6.56%. Cytokinetics has a consensus target price of $57.21, suggesting a potential upside of 62.59%. Given Cytokinetics' higher probable upside, analysts plainly believe Cytokinetics is more favorable than Reata Pharmaceuticals.
Reata Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Cytokinetics received 405 more outperform votes than Reata Pharmaceuticals when rated by MarketBeat users. Likewise, 80.47% of users gave Cytokinetics an outperform vote while only 66.99% of users gave Reata Pharmaceuticals an outperform vote.
Cytokinetics has a net margin of -410.89% compared to Reata Pharmaceuticals' net margin of -9,897.91%. Reata Pharmaceuticals' return on equity of -922.50% beat Cytokinetics' return on equity.
76.1% of Reata Pharmaceuticals shares are held by institutional investors. 28.7% of Reata Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Cytokinetics beats Reata Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RETA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reata Pharmaceuticals Competitors List
